All items sold for research purposes only.  –  Call or Text (860) 845-6557
Free shipping on orders over $150  ·  Domestic Manufacturing  ·  Third-party Tested
0 Support
Peptides

What Is Gonadorelin? A Research Overview

Explicit Research  ·  Research Compound Overview
← Back to Articles
Research Use Only. Gonadorelin is sold by Explicit Research exclusively for laboratory and research purposes. This article summarizes published preclinical and experimental literature. It is not medical advice and does not constitute a recommendation for human use. All compounds are for in vitro and animal research only.

All information below describes the compound's chemical identity, laboratory handling, and the published research literature. It describes molecular targets and results in laboratory and animal models only — not effects in humans — and is not evidence of any human benefit.

What Is Gonadorelin?

Gonadorelin is a synthetic decapeptide whose amino acid sequence is identical to endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide first isolated and structurally characterized by Schally and colleagues in 1971. It belongs to the releasing-hormone class of peptides and acts at the gonadotropin-releasing hormone receptor (GnRHR) expressed on pituitary gonadotroph cells. It does not occur as a distinct synthetic entity in nature; it is a chemically synthesized copy of the native hormone used as a reference compound in endocrine research.

It is supplied as a reference compound for in vitro and animal research use only. The sections below summarize its chemical identity, laboratory handling, the molecular targets and model systems examined in the published literature, and the primary references — without describing outcomes, efficacy, or effects in humans.

Research Targets & Pathways

Published preclinical literature has examined Gonadorelin in relation to several molecular systems. These are pathway associations reported in laboratory and animal models; refer to the cited studies for methods and findings.

Model Systems Studied

Gonadorelin has been used as a test compound across a range of published preclinical model systems, spanning livestock, non-human primate, rodent, and in vitro cell assays. Refer to the cited literature for study designs, endpoints, and findings.

Note: several of the cited Gonadorelin studies are recent (2025–2026) publications; independent replication of the newer findings remains ongoing.

Molecular & Technical Profile

C55H75N17O13  |  MW 1182.34 g/mol  |  CAS 33515-09-2  |  Sequence: decapeptide, identical to endogenous GnRH

Storage, Reconstitution & Working Concentrations

Lyophilized storage−20°C, protected from light and moisture; reported stable ~24 months under recommended conditions; confirm lot-specific expiry via COA
Reconstituted storage2–8°C up to ~28 days; avoid repeated freeze–thaw — aliquot into single-use volumes prior to freezing for long-term storage
SolubilityFreely soluble in water and aqueous buffers (e.g. sterile PBS, pH 7.0–7.4); also soluble in dilute acetic acid (0.1% v/v); avoid prolonged strongly alkaline pH
ReconstitutionEquilibrate vial to room temperature 10–15 min; add sterile water for injection (or 0.1% acetic acid) slowly down the vial wall; swirl gently — do not vortex; let stand 2–3 min if needed to clarify
Stock solution1 mg/mL in sterile water for injection or 0.1% acetic acid; further dilute in PBS (pH 7.4) or culture medium to working concentration
In vitro working range1 nM – 1 µM (~0.001–1 µg/mL) in GnRH receptor binding and cAMP/IP3 assays; 1–100 nM in pituitary gonadotroph stimulation assays for LH/FSH release; confirm per cell line or assay format
Animal model dosingSee cited literature for model-specific concentration ranges and administration protocols
Endotoxin<1 EU/mg (LAL assay); confirm lot-specific COA before use in sensitive cell systems

Storage, reconstitution, and working-concentration values are general laboratory guidance for in vitro and animal research; always confirm against the lot-specific Certificate of Analysis.

Current Research Status

Gonadorelin is the synthetic form of the endogenous decapeptide gonadotropin-releasing hormone (GnRH), and gonadorelin salts have been marketed as approved pharmaceutical products — for example, gonadorelin hydrochloride under the brand name Factrel and gonadorelin acetate under the brand name Lutrepulse. The research-grade material supplied by Explicit Research is a reference compound for laboratory research use only; it is not that drug product and is not intended for human or veterinary use. The published literature on gonadorelin spans foundational endocrinology (structural characterization of GnRH and the pituitary GnRH receptor), pituitary and reproductive model systems, and more recent work. Several of the cited studies are recent (2025–2026) publications for which independent replication is ongoing.

Research FAQ

Is Gonadorelin approved for human use?

Gonadorelin is the synthetic form of the endogenous decapeptide GnRH, and gonadorelin salts have been marketed as approved pharmaceutical products (for example, gonadorelin hydrochloride under the brand name Factrel and gonadorelin acetate under the brand name Lutrepulse). The research-grade material supplied by Explicit Research is a reference compound for laboratory research use only — it is not that drug product and is not for human or veterinary use.

What is Gonadorelin's molecular formula and sequence?

A synthetic decapeptide with an amino acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH) — molecular formula C55H75N17O13, MW 1182.34 g/mol, CAS 33515-09-2.

How is Gonadorelin stored and reconstituted?

Store lyophilized at −20°C, protected from light and moisture. Reconstitute in sterile water for injection or 0.1% acetic acid added slowly down the vial wall, swirling gently (do not vortex); store the reconstituted solution at 2–8°C for up to ~28 days and avoid repeated freeze–thaw.

What targets and model systems has Gonadorelin been studied in?

Preclinical work has examined the GnRH receptor (GnRHR), the hypothalamic–pituitary–gonadal axis, gonadotropin (LH/FSH) secretion, and pulsatile versus continuous signaling paradigms — across ovariectomized ewe, primate, rodent, mouse, and dairy goat models and in vitro pituitary gonadotroph and hormone-responsive cell assays. Note the recent-publication caveat noted above.

Selected References

  1. Schally A V, et al. (1971). Isolation and structural characterization of hypothalamic luteinizing hormone-releasing factor. Science.
  2. Knobil E, et al. (1980). Pulsatile GnRH secretion pattern and its role in governing LH release from the anterior pituitary. Science.
  3. Clarke I J, Cummins J T (1982). Gonadotropin-releasing hormone pulse frequency and amplitude regulation of LH and FSH secretion measured in ovariectomized ewes. Endocrinology.
  4. Bhatt et al. (2026). Sex-differentiated transcriptional activity of GnRH1/GnRHR1 signaling pathway examined in hamster model. Life (Basel).
  5. Stojilkovic S S, Catt K J (1988). Mechanisms of GnRH receptor binding, internalization, and downstream signal transduction cascade characterized in pituitary cells. Endocr Rev.
  6. Crowley W F, et al. (1980). Pulsatile GnRH administration measured for restoration of gonadotropin secretion in hypogonadotropic animal models. J Clin Endocrinol Metab.
  7. Belchetz P E, et al. (1978). Continuous vs. pulsatile GnRH infusion compared for LH/FSH suppression vs. stimulation outcomes in primate pituitary. Science.
  8. Bhatt et al. (2026). GABA receptor modulation of arcuate kisspeptin neuron bursting and synchronization activity measured in female mouse model, informing upstream GnRH pulse generation. J Neuroendocrinol.
  9. Palomba S, et al. (2026). Anovulation model outcomes reviewed across GnRH-axis interventions including clomiphene, comparing ovulation rates and cycle restoration endpoints. Gynecol Endocrinol.
  10. Yildiz et al. (2026). GnRH-based estrus synchronization protocols assessed for progesterone levels, metabolic profile, and reproductive performance endpoints in dairy goat model. Anim Sci J.
  11. Filicori M, et al. (1988). Pulsatile GnRH therapy measured for ovulation induction rates and gonadotropin response profiles in women with hypothalamic amenorrhea. J Clin Endocrinol Metab.
  12. Balen A H, Jacobs H S (1994). GnRH pulse delivery regimens assessed for LH surge triggering and follicular development metrics in anovulatory subjects. Hum Reprod.
  13. Chen et al. (2026). Ovarian response and AMH-based reserve markers measured following GnRH agonist co-administration in emergency fertility preservation protocols in hematological disease cohort. Reprod Med Biol.
  14. Wang et al. (2026). Triple-step surgical and GnRH agonist protocol assessed for AMH decline and ovarian reserve preservation endpoints in giant endometrioma management. Case Rep Obstet Gynecol.
  15. Blumenfeld Z, et al. (2015). GnRH agonist co-treatment measured for ovarian follicle pool preservation and POI incidence reduction during gonadotoxic chemotherapy in animal and clinical models. Hum Reprod Update.
  16. Del Mastro L, et al. (2011). Ovarian function markers including FSH and AMH measured after GnRH analog co-administration during breast cancer chemotherapy protocols. JAMA.
  17. Conn P M, Crowley W F (1991). GnRH receptor internalization kinetics and downregulation measured in pituitary gonadotroph cell lines. Annu Rev Med.
  18. Limonta P, et al. (1999). GnRH receptor-mediated antiproliferative signaling measured in hormone-responsive tumor cell lines, characterizing extra-pituitary receptor activity. Endocrinology.
  19. Zhao et al. (2025). Adverse event profile differences quantified across long-acting GnRH analog classes using real-world pharmacovigilance database analysis. PLoS One.
  20. Schirpenbach C, Reincke M (2009). Safety signal and bone mineral density loss measured in long-term GnRH agonist exposure models. Eur J Endocrinol.
  21. Conn P M, Bhalla V K (2004). GnRH analog dose-response variability and species-specific receptor affinity noted as key translational limitations in preclinical-to-clinical modeling. Mol Cell Endocrinol.